Brief: Lavipharm Signs Strategic Commercial Agreement With iNova Pharmaceuticals

Lavipharm SA

23/01/2025 07:54

Jan 23 (Reuters) - Lavipharm SA  LPHr.AT :
    * ANNOUNCES STRATEGIC COMMERCIAL AGREEMENT WITH INOVA
PHARMACEUTICALS OWNER OF THE BETADINE BRAND
    * AGREEMENT GRANTS INOVA COMMERCIAL DISTRIBUTION RIGHTS FOR
A NEW
LAVIPHARM-DEVELOPED ANTISEPTIC OTC DRUG IN 60 COUNTRIES
    * THE DRUG HAS ALREADY RECEIVED INITIAL EUROPEAN REGULATORY
APPROVAL AND IS EXPECTED TO LAUNCH IN THE LAST QUARTER OF THE
YEAR
    * LAVIPHARM SAYS IT WILL MANUFACTURE THE PRODUCT AT ITS
PAIANIA
FACILITIES FOR MOST INTERNATIONAL MARKETS AND WILL ALSO LAUNCH
IT IN GREECE


Further company coverage:  LPHr.AT 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))